the release of il-31 and il-13 after nasal allergen challenge and their relation to nasal symptomsil-31的释放和鼻过敏原后il-13挑战及其与鼻症状.pdfVIP

Baumann et al. Clinical and Translational Allergy 2012, 2:13 /content/2/1/13 RESEARCH Open Access The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms 1* 1 1 1 1 Ralf Baumann , Matthaeus Rabaszowski , Igor Stenin , Maria Gaertner-Akerboom , Kathrin Scheckenbach , 2 1 1 Jens Wiltfang , Joerg Schipper and Martin Wagenmann Abstract Background: IL-31, a recently discovered member of the gp130/IL-6 cytokine family, is mainly expressed by human mast cells and T helper type 2 cells. IL-31 is a key trigger of atopic dermatitis. Recent studies also suggest a role of IL-31 in the pathogenesis of other allergic diseases including allergic rhinitis. In the present study we studied the release of IL-31 and IL-13 in allergen-challenged allergic rhinitis patients. Methods: Seven seasonal allergic volunteers underwent unilateral nasal provocation with allergen (and a control challenge) with the disc method out of the allergy season. Nasal symptom scores (rhinorrhea, itching, sneezing, obstruction) and bilateral nasal secretions were quantified before and after allergen provocation. IL-13 and IL-31 in nasal secretions and serum were measured by electrochemiluminescent immunoassay or ELISA, respectively. Results: Nasal allergen challenge induced the typical clinical symptoms and physiological changes. IL-31 and IL-13 in nasal secretions increased in four and five, respectively, volunteers at 5 h after allergen but not after control challenge. We observed correlation trends between nasal IL-31 concentrations and IL-13 concentrations (r = 0.9, p = 0.002), and IL-31 contents and sym